Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "eye"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
Showing
1
-
20
of
25
Search:
'"eye"'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Pharmacoeconomic review report: Cyclosporine (Verkazia) (Santen Canada inc.) : indication: treatment of severe vernal keratoconjunctivitis in children from four years of age throug...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... with the use of corticosteroids and
eye
drops based on the VEKTIS trial. In the manufacturer's base case...
”
Read Now
2
Pharmacoeconomic review report: Latanoprostene bunod (Vyzulta) : (Bausch Health Canada Inc.)
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
...). It is available as a sterile topical ophthalmic solution containing 0.24 mg/mL LBN supplied in an
eye
-drop...
”
Read Now
3
Pharmacoeconomic review report: Cyclosporine (Verkazia) (Santen Canada inc.) : indication: treatment of severe vernal keratoconjunctivitis in children from four years of age throug...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... with the use of corticosteroids and
eye
drops based on the VEKTIS trial. In the manufacturer's base case...
”
Read Now
4
Pharmacoeconomic review report: Latanoprostene bunod (Vyzulta) : (Bausch Health Canada Inc.)
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
...). It is available as a sterile topical ophthalmic solution containing 0.24 mg/mL LBN supplied in an
eye
-drop...
”
Read Now
5
Clinical review report: Preservative-free latanoprost 50 [m]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... antiglaucoma medications. Patients with OSD may experience dry
eye
or sensations of burning, stinging, itching...
”
Read Now
6
Clinical review report: Preservative-free latanoprost 50 [m]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... antiglaucoma medications. Patients with OSD may experience dry
eye
or sensations of burning, stinging, itching...
”
Read Now
7
Clinical review report: Dexamethasone (Ozurdex) (Allergan, Inc.) : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... segment of the
eye
, and for the treatment of adult patients with diabetic macular edema (DME) who...
”
Read Now
8
Pharmacoeconomic review report: Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops) : (Recordati Rare Diseases Canada Inc.)
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
... with cystinosis. The recommended dose for CH 0.55% is one drop of solution in each
eye
, four times per day during...
”
Read Now
9
Clinical review report: Voretigene neparvovec (Luxturna) : (Novartis Pharmaceuticals Canada Inc.) : indication: vision loss, inherited retinal dystrophy
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
... effects of voretigene neparvovec administered as a single dose of 1.5 × 1011 vector genomes in each
eye
...
”
Read Now
10
Clinical review report: Dexamethasone (Ozurdex) (Allergan, Inc.) : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... segment of the
eye
, and for the treatment of adult patients with diabetic macular edema (DME) who...
”
Read Now
11
Ketamine for adult patients who have suffered painful and traumatic injuries : a review of clinical effectiveness, cost-effectiveness, safety, and guidelines
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... brain or
eye
injury. This report will also review the evidence around the optimal dose of ketamine...
”
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Voretigene neparvovec (Luxturna -- Novartis Pharmaceuticals Canada Inc.) : indication : vision loss, inherited retinal dystroph...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... for subretinal injection and the Health Canada-approved dose is 1.5 x 1011 vector genomes (vg) for each
eye
...
”
Read Now
13
Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... solution with a recommended dose of one drop in the affected
eye
(s) per day. The manufacturer is requesting...
”
Read Now
14
Pharmacoeconomic review report: Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Published 2018
CADTH
“
... is one drop in the affected
eye
(s) once daily. The manufacturer-submitted price was $20.54 per pack of 30...
”
Read Now
15
Pharmacoeconomic review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... solution with a recommended dose of one drop in the affected
eye
(s) per day. The manufacturer is requesting...
”
Read Now
16
Pharmacoeconomic review report: Preservative-free latanoprost 50 [mu]g/mL ophthalmic solution (Monoprost) (Laboratoires Théa)
Published 2018
CADTH
“
... is one drop in the affected
eye
(s) once daily. The manufacturer-submitted price was $20.54 per pack of 30...
”
Read Now
17
Laser refractive surgery for vision correction : a review of clinical effectiveness and cost-effectiveness
by
Tran, Khai
,
Ryce, Andrea
Published 2018
CADTH
“
... to avoid corrective
eye
wear, patient satisfaction and quality of life. Cost-effectiveness of laser...
”
Read Now
18
Laser refractive surgery for vision correction : a review of clinical effectiveness and cost-effectiveness
by
Tran, Khai
,
Ryce, Andrea
Published 2018
CADTH
“
... to avoid corrective
eye
wear, patient satisfaction and quality of life. Cost-effectiveness of laser...
”
Read Now
19
Pharmacoeconomic review report: Dexamethasone (Ozurdex) (Allergan Inc.)
Published 2018
CADTH
“
... injection to be administered per
eye
-- re-administered when there is presence of macular edema. The price...
”
Read Now
20
CADTH Canadian Drug Expert Committee recommendation: Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.) : indication : for the reduction of intraocular pressure (IOP) in...
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
... documented diagnosis of open-angle glaucoma or ocular hypertensionin one or both
eyes
. Pricing condition...
”
1
2
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Year of Publication
From:
To:
Classification
610 - Medicine & health
16
330 - Economics
7
700 - The arts; fine & decorative arts
2
Language
English
25
Collection
National Center for Biotechnology Information
25
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
5
Butcher, Robyn
2
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
2
Li, Yan
2
Ryce, Andrea
2
more ...
Tran, Khai
2
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&lookfor=%22eye%22&type=AllFields
Send by Email
×
Loading...